A. Mills

发表

Mobilisation strategies for normal and malignant cells

J. Rasko, S. Nilsson, I. Lewis, 2011, Pathology.

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

J. Melo, A. Schwarer, J. Seymour, 2013, Blood.

Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells

A. Schwarer, J. Seymour, D. White, 2018, Leukemia.

Running head: Imatinib Cessation After Stable UMRD in CML

J. Melo, A. Schwarer, J. Seymour, 2017 .

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

J. Melo, A. Schwarer, J. Seymour, 2010, Leukemia.

Accelerated Delivery of Rituximab Is Safe on an Out-Patient Basis.

P. Marlton, D. Gill, R. Bird, 2005 .

Idarubicin Dose Escalation During Consolidation Therapy for Adult Acute Myeloid Leukemia.

L. Campbell, J. Szer, I. Lewis, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Hyper‐CVAD chemotherapy regimen has an adverse long‐term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization

P. Marlton, H. Prince, D. Gill, 2006, Hematological oncology.

The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early.

J. Reynolds, A. Schwarer, J. Seymour, 2008 .

A low‐dose rituximab regimen for first‐line treatment of acquired haemophilia A

J. Mason, J. Robertson, Joel T Collins, 2021, European journal of haematology.

Treatment of aplastic anaemia with lower‐dose anti‐thymocyte globulin produces similar response rates and survival as per standard dose anti‐thymocyte globulin schedules

J. Butler, K. Morris, G. Kennedy, 2016, Internal medicine journal.

Successful maintenance of molecular remission in chronic myelogenous leukaemia during pregnancy with transition from imatinib to pegylated interferon

A. Mills, M. Ellis, 2015, Internal medicine journal.

Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy.

Deborah L White, Simon Durrant, Susan Branford, 2008, Blood.

TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.

C. Tam, A. Schwarer, D. White, 2015, Blood.

Hypercalcaemia caused by Pneumocystis carinii pneumonia while in leukaemic remission.

J. McCormack, S. Wright, A. Mills, 1999, Australian and New Zealand journal of medicine.

Selective accumulation of virus-specific CD8+ T cells within the peripheral blood stem cell compartment.

M. Gandhi, Sanjleena Singh, K. Grimmett, 2009, Blood.

Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia.

J. Bashford, T. Olsen, C. Kelly, 1999, Australian and New Zealand journal of medicine.

Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial

A. Schwarer, D. White, T. Hughes, 2010 .

Two Year Data from a Prospective Safety Study Analyzing the Consequences of Imatinib Mesylate Inhibition of Sensitive Kinases Other Than bcr-abl in Patients with Previously Untreated Chronic Phase CML.

J. Reynolds, A. Schwarer, J. Seymour, 2006 .

Upfront Imatinib Therapy in CML Patients with Rapid Switching to Nilotinib for Failure to Achieve Molecular Targets or Intolerance Achieves High Overall Rates of Molecular Response and a Low Risk of Progression - An Update of the TIDEL-II Trial

A. Schwarer, D. White, T. Hughes, 2011 .

The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia

C. Tam, M. Lasica, J. Butler, 2019, Leukemia & lymphoma.

Early Switch to Nilotinib Does Not Overcome the Adverse Outcome for CML Patients Failing to Achieve Early Molecular Response On Imatinib, Despite Excellent Overall Outcomes in the TIDEL II Trial

A. Schwarer, D. White, T. Hughes, 2012 .

How we mobilize haemopoietic stem cells

J. Rasko, J. Szer, J. Lévesque, 2011, Internal medicine journal.

Ponatinib Facilitates Treatment-Free Remission By Inducing Deep Molecular Responses

S. Mapp, P. Eliadis, J. Morton, 2016 .

Chronic myeloid leukaemia and tyrosine kinase inhibitor therapy: assessment and management of cardiovascular risk factors

K. Kostner, B. Ko, J. Shortt, 2018, Internal medicine journal.

Trends in Outcomes in Australia and New Zealand in Autologous Stem Cell Transplantation in Older Patients with Multiple Myeloma: An Australasian Bone Marrow Transplant Recipient Registry Study

I. Kerridge, C. Tiley, S. Harrison, 2020 .

Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance

M. Gleeson, C. Tam, M. Gilbertson, 2023, Haematologica.

Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention

Paul P. S. Wang, D. Thomson, H. Scott, 2023, Haematologica.

Mobilisation strategies for normal and malignant cells

S. Nilsson, I. Lewis, J. Lévesque, 2011, Pathology.